What is Zaleplon?
Category: Prescription Drugs
Most popular types: Sonata
Zaleplon is a sedative/hypnotic drug used in the treatment of insomnia.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Insomnia | 132 | 17 | |
| Insomnia | 44 | 18 | |
| Anxious mood | 1 | 0 | |
| Difficulty staying asleep | 1 | 0 | |
| Major depressive disorder | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 3 | |
| Moderate | 2 | |
| Mild | 9 | |
| None | 31 |
Commonly reported side effects and conditions associated with Zaleplon
| Side effect | Patients | Percentage |
|---|---|---|
| Drowsiness | 2 | |
| Rebound insomnia | 2 | |
| Dry mouth at night | 1 | |
| Excessive sleeping (hypersomnia) | 1 | |
| Flashbacks | 1 | |
| Grogginess | 1 |
Why patients stopped taking Zaleplon
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Did not seem to work | 28 | |
| Doctor's advice | 13 | |
| Other | 13 | |
| Side effects too severe | 8 | |
| Expense | 5 | |
| Change in health plan coverage | 2 | |
| Course of treatment ended | 2 | |
| Personal research | 1 |
Duration
Stopped taking Zaleplon
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 17 | |
| 1 - 6 months | 15 | |
| 6 months - 1 year | 11 | |
| 1 - 2 years | 8 | |
| 2 - 5 years | 5 | |
| 5 - 10 years | 1 | |
| 10 years or more | 2 |
What people switch to and from
Patients started taking Zaleplon after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Zolpidem (Ambien) | 8 | |
| Quetiapine (Seroquel) | 2 | |
| Cyclobenzaprine (Flexeril) | 1 | |
| Eszopiclone (Lunesta) | 1 | |
| Ramelteon (Rozerem) | 1 |
Patients stopped taking Zaleplon and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Trazodone (Apo-Trazodone) | 3 | |
| Quetiapine (Seroquel) | 2 | |
| Zolpidem (Ambien) | 2 | |
| Doxepin (Sinequan) | 1 | |
| Eszopiclone (Lunesta) | 1 |
Last updated: